News Provided by GlobeNewswire2021-04-10
SAN FRANCISCO, April 10, 2021 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will host a conference call to discuss the recent publication by Novitas Solutions (“No....Read more
News Provided by GlobeNewswire2021-04-10
ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and well-tolerated Identified recommended Phase 2 dose for ZN-c3 to be 300 mg QD with continuous dosing Announces plan to start Phase 1/2 osteosarcoma trial in ....Read more
News Provided by GlobeNewswire2021-04-10
Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional immunotherapy responsive patients missed by commonly used biomarkers Data supports potential utility of ....Read more
News Provided by GlobeNewswire2021-04-10
PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activityRobust in vivo tumor regression observed with once daily oral dosingPharmacodynamic biomarkers of p53 activation developed for clinical trialsPC14586 is being tested in a Phase 1/2 clinical trial in patients with advance....Read more
News Provided by GlobeNewswire2021-04-10
TH1902 anti-tumor post-treatment effect persists longer than with docetaxel aloneMONTREAL, April 10, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, t....Read more
News Provided by GlobeNewswire2021-04-10
Study Confirms F-star’s Bispecific Antibody Tetravalency is the Most Efficient Way to Induce Receptor Clustering and ActivationCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company ....Read more
News Provided by GlobeNewswire2021-04-10
CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today presented prec....Read more
News Provided by GlobeNewswire2021-04-10
7 objective responses observed to date in multiple tumor typesNew responses reported in patients with melanoma and ovarian cancerBenefit seen in patients typically unresponsive to I-O agents LEXINGTON, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company....Read more
News Provided by GlobeNewswire2021-04-10
KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior antitumor activity in MYD88-mutant DLBCL models compared to IMiDs or selective IRAK4 targeting alone Company anticipates IND submission and, if cle....Read more
News Provided by GlobeNewswire2021-04-10
Bolt’s first-in-class clinical candidate, BDC-1001, is a novel HER2-targeting, TLR 7/8 immune-stimulating antibody conjugate (ISAC) currently in an ongoing Phase 1/2 first-in-human studyREDWOOD CITY, Calif., April 10, 2021 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT), a clinical....Read more
Load More
